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SUMMARY
Aims: Early-life seizures, particularly when prolonged, may be harmful to the brain. Cur-
rent pharmacotherapy is often ineffective; therefore, novel neuro- and/or glio-transmitter
systems should be explored for targeting. The P2X7 receptor is a cation-permeable channel
with trophic and excitability effects on neurons and glia which is activated by high amounts
of ATP that may be released in the setting of injury after severe seizures. Here, we tested the
effects of A-438079, a potent and selective P2X7 receptor antagonist in a lesional model of
early-life status epilepticus.Methods: Seizures were induced by intra-amygdala kainic acid
in 10-day-old rat pups. Electrographic seizure severity, changes to P2X7 receptor expres-
sion, inflammatory responses and histological effects were evaluated. Results: Seizures
induced by intra-amygdala kainic acid increased levels of P2X7 receptor protein and inter-
leukin-1b and caused significant cell death within the ipsilateral hippocampus. A-438079
rapidly reached the brain following systemic injection in P10 rats. Intraperitoneal injection
of A-438079 (5 and 15 mg/kg) 60 min after triggering seizures reduced seizure severity and
neuronal death within the hippocampus. A-438079 had superior neuroprotective
effects compared with an equally seizure-suppressive dose of phenobarbital (25 mg/kg).
Conclusions: These results suggest P2X7 receptor antagonists may be suitable as frontline
or adjunctive treatments of pediatric status epilepticus or other early-life seizures, particularly
when associated with brain damage.
Introduction
Seizures during the first month of life (neonatal seizures) are more
common than at any other time of life [1,2], while status epilepti-
cus (SE) is the most common neurological emergency of child-
hood [1–3]. Although the immature brain is more susceptible to
seizures, it is less vulnerable to cell death [4]. Nevertheless, the
risk of neurological damage after SE in childhood [5] and increas-
ing concerns that neonatal seizures are harmful [6,7] underscores
the need for prompt and effective pharmacotherapy. Treatment
for pediatric SE begins with benzodiazepines such as lorazepam,
followed by phenobarbital or other anti-epileptic drugs [8]. Phe-
nobarbital remains the frontline treatment for neonatal seizures
[9,10]. Unfortunately, the efficacy of these treatments for seizures
in the developing brain is often inadequate, which has been attrib-
uted to brain maturational aspects of the glutamate and c-amino
butyric acid (GABA) systems, chloride gradients, and loss of GABA
receptor function [9,11].
If prolonged seizures are harmful to the immature brain and
current therapies are ineffective, then alternate targets for
achieving seizure suppression must be identified. An optimal
approach might be to combine the necessary anti-excitatory
effects with anti-inflammatory or neuroprotective properties.
ATP is an important neuro- and glio-transmitter in the nervous
system that mediates depolarizing responses via the P2X class of
ligand-gated ion channels [12,13]. In addition to effects on neu-
rotransmitter release [14–18], the P2X7 receptor (P2X7R) has
important trophic actions on microglia [19] and astrocytes [20] or
can promote glial cell death [21,22]. As a result, there has been
significant interest in the role of the P2X7R in neurological disor-
ders [23,24]. Recent work in adult rodent SE models has shown
that drugs acting on the P2X7R can have potent anticonvulsant
effects [25,26]. P2X7R inhibition reduced seizure severity, neuro-
nal death, microglia activation and interleukin-1b (IL1b) levels
when SE was triggered by intra-amygdala kainic acid (KA) in
mice, a model associated with a focal hippocampal lesion [25,26].
In contrast, P2X7R signaling did not affect seizures after systemic
KA or picrotoxin, which are nonlesional models [27]. These
differences may be due to a high ATP requirement for the delete-
rious effects of P2X7R activation to manifest, and this may be
556 CNS Neuroscience & Therapeutics 20 (2014) 556–564 ª 2014 John Wiley & Sons Ltd
achieved only in the setting of neuronal activity sufficient to pro-
duce excitotoxic injury [24,28].
It is unknown whether P2X7R ligands have effects against
seizures in the developing brain. To test this idea, we evaluated
A-438079, a potent and selective brain permeable antagonist of
the P2X7R [29] against SE induced by intra-amygdala microin-
jection of KA in postnatal day 10 (P10) rats [30], an age-
appropriate model of a human full-term newborn to 1 year of
age [4,31].
Materials and methods
Intra-amygdala KA-induced SE in P10 Rats
Animal procedures were performed as before [30] and were
reviewed and approved by the RCSI Research Ethics Committee
and conducted under license from the Department of Health and
Children, Dublin, Ireland. Animals were maintained on a 12 h
light:dark cycle with access to food and water provided ad libitum.
Male or female Sprague–Dawley rat pups (P10; 17–23 g; Harlan,
UK) were separated from the dam, anesthetized with isoflurane,
and placed in a stereotaxic frame equipped with a neonatal rat
adaptor. Body temperature was maintained at 37°C using a feed-
back-controlled heat blanket (Harvard Apparatus Ltd, Kent, UK).
Following a midline scalp incision, three partial cranial holes were
drilled on the skull surface for placement of Electroencephalogram
(EEG) screw electrodes (Bilaney Consultants Ltd, Sevenoaks, UK;
see Figure 1A). A complete craniectomy was drilled for the place-
ment of a guide cannula for the intra-amygdala injection. Coordi-
nates from bregma were AP: 1.4 mm and L: +2.9 mm. The guide
cannula was lowered to rest on the brain surface and the entire
assembly fixed with dental cement. Pups were then placed in an
incubator at nest temperature (35  1°C) to recover from surgery
for 30 min prior to further experimentation.
For induction of status epilepticus and EEG recordings, pups
were placed in a 40 cm 9 20 cm 9 20 cm open container. The
cortical electrodes were connected by a 6-channel cable (Bilaney
Consultants Ltd) to a Grass Comet lab-based EEG and EEG moni-
tored using TWin EEG software (Natus Neurology Inc, Warwick,
RI, USA). Baseline EEG traces were recorded for 10 min, and
then, a 31-gauge internal cannula was inserted into the lumen of
the guide cannula and lowered 3.5 mm below cortical surface to
target the central and basolateral amygdala (Figure 1A). KA (2 lg
in 0.2 lL of phosphate-buffered saline [PBS, pH 7.4]) was injected
through the cannula using a 1-lL Hamilton syringe. EEG was
recorded for 2 h after KA, and then, pups were disconnected and
returned to the dam. Typical maternal separation time was 3 h
per pup.
EEG data were exported to Labchart 7 (AD Instruments Ltd,
Oxford, UK) for analysis. The effects of drug treatments on EEG
were determined for the 60 min recording period after injection.
Mean amplitude, total power and high-amplitude spikes were
calculated. Each trace was also converted to its absolute value to
calculate the mean amplitude. The total power was automatically
measured by the software with the default frequency range of
0–500 Hz. The spike count represents the number of high-ampli-
tude spikes >50 lV and was calculated with the spike histogram
module.
Drug Treatments
Animals were randomized to treatment groups, drugs were deliv-
ered via an intraperitoneal injection in 0.3 mL volume, 1 h after
KA injection. A-438079 (Tocris Bioscience, Bristol, UK) was
dissolved in water and given at 0.5, 5, 15, and 50 mg/kg. Pheno-
barbital was used at 25 mg/kg and bumetanide (Sigma-Aldrich,
Arklow, Ireland) at 0.15 and 1 mg/kg.
Histopathology and Immunohistochemistry
Rats were killed by barbiturate overdose and saline perfused to
remove intravascular blood. Fluoro-jade B staining (FJB) was
used to identify acutely degenerating neurons as described
[25]. Briefly, fresh-frozen tissue sections at the level of the
dorsal hippocampus were postfixed, dehydrated, immersed in
0.06% KMnO4 solution followed by a rinse and then stained
with 0.001% w/v FJB (Millipore Ireland B.V., Tullagreen, Ire-
land). Staining was examined using an epifluorescence micro-
scope (Nikon 2000s), and positive cells within the
hippocampus were counted in a blinded fashion under 209
magnification, as described [25]. Representative images were
obtained using an Orca 285 camera and processed using
Wasabi software (Hamamatsu Photonics Germany GmbH,
Herrsching, Germany). Images were converted to grayscale and
inverted such that degenerated neurons appeared dark on a
light background.
Assessment of irreversible DNA fragmentation was performed
using a terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) technique, according to manufacturer’s instruc-
tions (Promega UK, Southampton, UK). Staining was examined
and quantified as above.
For P2X7R immunohistochemistry, sections were permeabi-
lized and blocked in goat serum followed by incubation with
antibodies against P2X7R (1:200; Alomone Labs, Jerusalem,
Israel), NeuN (1:500; Millipore Ireland B.V.), or synaptophysin
(1:500; Sigma-Aldrich) overnight at 4°C. Sections were
washed and incubated with goat polyclonal secondary
antibodies coupled to AlexaFluor 488 or AlexaFluor 568
(BioSciences, Dun Laoghaire, Ireland). To confirm specificity,
additional sections were incubated without the primary anti-
body. Nuclei were labeled by staining with 40 6-diamidino-2-
phenylidole (DAPI; Vector Laboratories, Burlingame, CA,
USA), and sections were examined under an epifluorescence
microscope. A semiquantitative 4-point scoring system was
used to assess neuronal survival in NeuN-stained tissue sec-
tions as follows: (0) no damage; (1) minor loss of NeuN stain-
ing in scattered neurons; (2) modest loss of NeuN staining in
CA3; (3) loss of NeuN staining in entire CA3; (4) loss of
NeuN staining throughout entire hippocampus including hilus
and CA1 area.
Western Blotting and IL1b Analysis
Western blotting was performed as previously described [25].
Briefly, hippocampus was homogenized in lysis buffer containing
a protease inhibitor cocktail and proteins separated using
SDS-PAGE. Proteins were transferred to nitrocellulose membranes
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and incubated with primary antibodies against the rat form of
the P2X7R (1:500; Alomone APR-004), IL1b (1:1000; Abcam
AB9722, Cambridge, UK), or b-Actin (1:5000; Abcam AB8227)
as a loading control. Proteins were visualized using a chemilu-
minescence kit, and bands captured using a Fujifilm LAS scan-
ner. Semiquantitative analysis of band density was performed
using Image J.
Measurement of Plasma and Brain Levels of A-
438079
To confirm A-438079 reached the brain after systemic administra-
tion, P10 rat pups were injected with 5 mg/kg A-438079 and
killed either 10 min, 30 min, or 2 h later (n = 4 per group). Blood
samples were centrifuged at 1000 9 g for 10 min to isolate the
(A) (B)
(C)
(D)
(E)
Figure 1 Status epilepticus and hippocampal damage following intra-amygdala kainic acid (KA) in P10 rat pups. (A) Schematic showing
experimental paradigm. KA (or vehicle) is injected into the amygdala of freely moving pups followed by 2-h recordings. Test drugs were delivered
after 60 min. Figure below depicts the stereotaxic level, surface-affixed recording electrodes and cannula placement for KA microinjection. (B) EEG
heat map depicting typical frequency-amplitude data during status epilepticus (SE). Note onset of continuous seizures shortly before 60 min post-
KA. (C) Representative EEG traces depicting electrographic seizure development following KA with increasing high-amplitude, high-frequency
spikes. (D) Semiquantitative analysis of EEG total power and spikes in the model. Note temporal development of seizure severity in second hour
compared to first. (E) Fluoro-jade B (FJB) staining of the ipsilateral hippocampus 72 h after SE. Damage extends from the hilus through the CA3
subfield as well as injury to the CA1-CA2 border. Scale bar in E, top; 250 lm, bottom; 60 lm. *P < 0.05 compared to baseline; #P < 0.05
compared to 1 h.
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plasma. Samples were analyzed using liquid chromatography–
mass spectrometry (LC-MS/MS) by a service provider (Cyprotex,
Macclesfield, UK). Briefly, protein was precipitated from 50 lL
aliquots of the individual plasma or brain tissue homogenate, and
A-438079 quantified by LC-MS/MS from a five-point standard
curve.
Data Analysis
Data are presented as the mean  standard error of the mean.
Two-group comparisons were made using Student’s t test and
multigroup comparisons using analysis of variance (ANOVA) fol-
lowed by Bonferroni post hoc test. Significance was accepted at
P < 0.05.
Results
Intra-amygdala KA in P10 Rats Produces
Prolonged Seizures and Damage to the
Ipsilateral Hippocampus
Intra-amygdala microinjection of KA in P10 rat pups produced sei-
zures resulting in damage to the ipsilateral hippocampus
(Figure 1). Seizures typically began within a few minutes of KA
injection, but EEG power remained only modestly elevated during
the first 30–40 min before increasing and developing into contin-
uous electrographic seizures from 45 to 50 min. Thereafter, sei-
zures became continuous and severe (Figure 1B–D). Consistent
with previous studies [30], the hippocampus from rat pups killed
72 h later displayed extensive FJB staining indicative of irrevers-
ible neuronal damage which was most prominent in the ipsilateral
CA3 subfield but also incorporated the hilus, occasional dentate
granule neurons, and CA1 pyramidal cells (Figure 1E).
Expression of P2X7R Following SE in P10 Rats
We next used Western blotting to detect protein for the receptor
in hippocampal homogenates. The protein for the P2X7R was lar-
gely undetectable in the hippocampus at P1 and P5, whereas a
band at the predicted molecular weight of ~75 kDa for the P2X7R
was observed in P10 and P30 rats (Figure 2A).
Following SE in P10 rats, P2X7R protein levels increased rapidly
and continued to increase at 24 and 72 h (Figure 2B). Confocal
microscopy revealed increased P2X7R immunoreactivity within
the hippocampus after SE (Figure 2C). This was prominent in the
stratum lucidum of the CA3 subfield which corresponds to the
mossy fiber terminals, a known site of P2X7R localization in the
rat [14]. Supporting these observations, P2X7R staining was clo-
sely localized with immunoreactivity for the synaptic marker syn-
aptophysin (Figure 2C). P2X7R activation is known to promote
(A)
(C)
(B)
(D)
Figure 2 P2X7R protein levels following
neonatal status epilepticus (SE). (A)
Representative Western blot (n = 1 per lane)
and graph (n = 4 per group) showing P2X7R
protein levels in the rat hippocampus at
postnatal day 1, 5, 10, and 30. (B)
Representative Western blot (n = 1 per lane)
and graph (n = 4 per group) showing P2X7R
protein levels increase following neonatal SE.
(C) Immunohistochemistry (4 h) showing (top)
P2X7R (green) staining within the stratum
lucidum (mossy fiber terminals) and around cell
bodies of NeuN-positive cells and (bottom)
P2X7R (red) with synaptophysin (syn, green).
Scale bar, 50 lm. (D) Graph quantifying IL1b
levels following neonatal SE (n = 5 per group).
*P < 0.05 compared with control.
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IL1b release [32], and we also detected an increase in IL1b protein
levels after SE in the model (Figure 2D).
Dose-dependent Effects of A-438079 on SE in
P10 Rats
To determine whether P2X7R antagonists had effects on SE, we
injected rat pups 1 h after KA with A-438079 over the dose range
0.5–50 mg/kg and recorded effects using surface EEG over the
next hour. At the lowest tested dose (0.5 mg/kg), A-438079 had
no significant effect on seizure severity (Figure 3A,B). In contrast,
seizure severity was reduced in rat pups given 5 or 15 mg/kg A-
438079 (Figure 3A,B). At either dose, EEG amplitude, total
power, and spike count were all reduced. At the highest tested
dose (50 mg/kg), an effect on amplitude remained but spike count
and overall EEG power were not significantly reduced compared
to vehicle (Figure 3A,B).
A-438079 Reduces Seizure-induced Neuronal
Death in P10 Rat Pups
We next examined neuronal damage in tissue sections obtained
72 h after SE. As expected, vehicle-treated SE pups displayed
extensive FJB staining of damaged neurons within the ipsilateral
hippocampus (Figure 4A,B). Seizure damage was significantly
reduced in pups that received either 5 or 15 mg/kg A-438079
(Figure 4A,B). Damage in the 0.5 and 50 mg/kg groups was not
different to vehicle-injected seizure pups (Figure 4B). Sections
from pups given the lowest effective A-438079 dose (5 mg/kg)
also showed reduced TUNEL staining, a marker of irreversible
DNA fragmentation (Figure 4C), and a lower score for neuronal
damage (Figure 4D). We also examined levels of IL1b in hippo-
campal lysates from rat pups 24 h after SE (Figure 4E). Rat pups
subject to SE and treated with vehicle had significantly increased
IL1b levels in the hippocampus (P < 0.05 compared with non-KA
veh/A-438079 alone, n = 4). In contrast, IL1b levels in rats sub-
ject to SE and treated with A-438079 were not different to nonsei-
zure controls (Figure 4E).
Plasma and Brain Levels of A-438079 Following
Systemic Injection in P10 Rats
A-438079 has previously been reported to be available in the
brain following systemic administration [29]. However, no study
has established the brain levels of A-438079 after systemic injec-
tion in immature rats. We therefore injected groups of P10 rats
with A-438079 (5 mg/kg, i.p.) and measured plasma and brain
levels 10, 30, and 120 min later. Plasma levels of A-438079
reached ~2.3 lg/mL at the 10 min time point, declining rapidly
thereafter (Figure 4F). Brain levels of A-438079 followed the
same profile, peaking at the earliest tested time and declining rap-
idly thereafter (Figure 4G).
(A) (B)
Figure 3 A-438079 suppresses neonatal
status epilepticus (SE). (A) Graphs quantifying
seizure parameters amplitude, spike count,
and total power for rat pups injected 60 min
after kainic acid (KA) with 0.5, 5, 15, and
50 mg/kg A-438079 compared with vehicle
(Veh; n = 7–14 per group). *P < 0.05
compared to Veh. (B) Representative EEG heat-
maps for each dose of A-438079 showing the
seizure-suppressive effect mainly at 5 and
15 mg/kg (frequency and amplitude scale
range same as for Figure 1B).
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Effects of Phenobarbital and Bumetanide on SE
Induced by Intra-amygdala KA in P10 Rats
We next compared the effects of A-438079 to phenobarbital, the
frontline treatment for neonatal seizures. As before, injection of
A-438079 (5 mg/kg) 60 min after KA resulted in significantly
reduced seizures in P10 rat pups (Figure 5A,B). Intraperitoneal
injection of rat pups with 25 mg/kg phenobarbital, a dose within
the range used in other studies of neonatal seizures [33,34],
reduced seizure severity by over 50%, although the effect was not
statistically superior to A-438079 (Figure 5A,B). No improvement
in anticonvulsant effects was obtained with the combination of A-
438079 plus phenobarbital (Figure 5A,B).
The NKCC1 (Na+, K+, 2Cl) cotransporter is responsible for the
high intracellular chloride concentration in the developing brain
and has been implicated in excitatory effects of GABA [35]. Bu-
metanide is an inhibitor of the NKCC1 transporter that has been
reported to inhibit seizures in nonlesional models of neonatal sei-
zures in P10 rats [36] and is in clinical trials for neonatal seizures
in the USA and Europe [37]. Accordingly, we investigated the
effects of bumetanide in the intra-amygdala KA model. Intraperi-
toneal injection of P10 rat pups with either 0.15 or 1 mg/kg bu-
metanide had no significant effect on EEG amplitude, total power,
or peak counts during seizures (Figure 5C and data not shown).
Analysis of FJB-stained tissue sections from the different groups
of rats revealed that while hippocampal damage was reduced in
rat pups injected with A-438079, seizure damage was not signifi-
cantly reduced in the rats treated with either phenobarbital or bu-
metanide (Figure 5D,F). Staining sections for DNA fragmentation
as a second marker of injury also revealed only A-438079 offered
significant protection in the model (Figure 5E,F). Intraperitoneal
injection of A-438079 alone had no effect on apoptosis in the
brain at either 5 or 50 mg/kg (Figure 5E and data not shown).
Discussion
In the present study, we report potent anticonvulsant effects of a
P2X7R antagonist in a model of early-life SE. We found A-438079
was centrally available after systemic injection and potently
reduced seizures triggered by intra-amygdala KA in P10 rats.
Although it was not more effective than phenobarbital at stopping
seizures, A-438079 provided potent protection against hippocam-
pal damage. These data suggest P2X7R antagonists may have
potential applications for the treatment of severe early-life
seizures.
Prolonged seizures in the developing brain are thought to be
harmful, and current practice is to treat with anticonvulsants.
Pharmacotherapy is often inadequate, however, with phenobarbi-
tal having limited efficacy against neonatal seizures and ben-
zodiazepines often failing to curtail seizures during pediatric SE
[8,10]. Thus, other neuromodulatory systems may represent suit-
able targets for the control of early-life seizures. Here, we investi-
gated the P2X7R, an ATP-activated ion channel that gates
depolarizing sodium and calcium entry into cells. Activation
requires high amounts of ATP, and the main hypothesis pursued
here was that if early-life seizures are sufficiently severe to pro-
duce hippocampal damage, the P2X7R would promote seizures
and their pathophysiological consequences, including neuroin-
flammation. We found A-438079 at 5 and 15 mg/kg strongly
reduced seizures triggered by intra-amygdala microinjection of
KA in P10 rats. At 10 days old, rat pups are thought to represent
the time from birth to 1 year in humans and are therefore suitable
(A) (B)
(C) (D)
(E) (F) (G)
Figure 4 Effects of A-438079 on hippocampal
injury after neonatal status epilepticus (SE). (A)
Representative fluoro-jade B (FJB) staining at
72 h from vehicle-injected SE pups and animals
that were given 5 mg/kg A-438079. Scale bar,
60 lm. (B) Graph showing FJB counts on
sections from dorsal hippocampus showing
protective effects of 5 and 15 mg/kg A-438079
(n = 5–9 per group). (C, D). Graphs showing
that A-438079 (5 mg/kg) also reduced (C)
TUNEL staining in the ipsilateral hippocampus
and (D) improved neuronal survival compared
to vehicle groups (n = 7–9 per group; (E)
Representative Western blot (n = 1 per lane)
showing induction of IL1b is reduced in rat
pups treated with A-438079 (5 mg/kg). Data
are representative of n = 4 independent
experiments. (F, G) Plasma and brain levels of
A-438079 measured after intraperitoneal
injection of 5 mg/kg (n = 3–4 per lane).
*P < 0.05 compared to vehicle.
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to model neonatal seizures and SE in the immature brain [4,31].
The seizures are sufficient to produce unilateral hippocampal scle-
rosis, and the model features a strong correlation between hippo-
campal damage and seizure severity [30]. In the design of our
study, we allowed seizures to develop before delivering the drug,
ensuring we evaluated in a realistic clinical scenario when seizures
or damage may already have begun. To our knowledge, our study
is the first to show an effect of a drug of this class on seizures in
the developing brain, and the data extend reports of anticonvul-
sant effects of A-438079 in adult mice subject to SE triggered using
the same focal-onset approach [25,26]. We also found that A-
438079 was strongly neuroprotective, reducing hippocampal
damage after SE in P10 rats by up to 80–90%. Thus, the present
study provides preclinical data supporting the targeting of the
ATP-gated P2X7R for the prevention of seizures and brain injury
after prolonged early-life seizures.
Relatively little is known about the developmental maturation
of ATP-gated signaling and the role of P2X7R in brain develop-
ment. The absence of brain abnormalities in mice lacking P2X7R
indicates the receptor is not required for normal brain develop-
ment [17,25,27,38]. In the present study, we detected the P2X7R
in hippocampal neurons and likely presynaptic terminals after sei-
zures in P10 rat pups, supporting other data on the presence of the
receptors in the rodent hippocampus [14,39,40].
Although we did not pursue the mechanism of seizure suppres-
sion by A-438079, it is likely to involve direct effects on neurons.
The receptor is known to be located presynaptically in the hippo-
campus [14], and blockade of P2X7R may reduce neurotransmit-
ter release [15–18]. P2X7R is expressed by microglia and
activation results in transformation to an active state and release
of IL1b [19,41,42], a potent convulsant in other early-life seizure
models [43]. Data here support an effect of A-438079 inhibiting
IL1b production, although we cannot exclude this being second-
ary to reduced seizures and tissue injury. The data fit with findings
in adult models where IL1b induction and microglia activation
was prevented by A-438079 [25]. By having dual effects, P2X7R
antagonists may suppress both seizures and proinflammatory
sequelae, which could be important in longer-term outcomes
where inflammation has been implicated in epileptogenesis [44].
A common feature of the models where anticonvulsive effects
are seen with P2X7R antagonists is the presence of early and sig-
nificant seizure-induced lesions to the hippocampus [25,26]. This
may release ATP or provoke glial and pro-inflammatory responses
where the contribution of P2X7R activation is uniquely patho-
genic [28]. Indeed, this may explain the lack of effects or even
opposite response in nonlesional adult SE models [27]. The mech-
anism of the neuroprotection in the present study is likely to be
mainly through seizure suppression, but P2X7R antagonists have
been reported to have direct neuroprotective effects in nonseizure
models [45–47].
In the present study, we also found phenobarbital had efficacy
against SE in the intra-amygdala KA model, reducing seizure
(A) (B) (C)
(D)
(F)
(E)
Figure 5 Comparison of A-438079 with
phenobarbital and bumetanide. (A, B) Graphs
showing EEG seizure parameters for rat pups
during neonatal status epilepticus (SE) given
either A-438079 (A-43, 5 mg/kg), phenobarbital
(PhB, 25 mg/kg), or a combination of both
(*P < 0.05 compared to vehicle; n = 5–6 per
group). (C) Graph quantifying EEG data after
neonatal SE in rat pups injected with
bumetanide (Bme; n = 6–7 per group). (D)
Fluoro-jade B (FJB) counts at the level of the
dorsal hippocampus showing protective
effects of A-438079, while damage persisted in
rat pups given either phenobarbital or
bumetanide (1 mg/kg) (n = 5–6 per group). (E)
TUNEL counts at 72 h in rat pups given drug
alone or 60 min after SE. Again, cell death is
reduced in the A-438079 group but not
following either phenobarbital or bumetanide
(n = 6 per group). (F) Representative FJB-
staining and TUNEL 72 h after SE in each
group. Note the reduced damage in the A-
438079-treated rat pups. Scale bar, top;
500 lm, bottom; 250 lm.
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severity by 60–70% although a complete dose-response analysis
was not undertaken. This is quite similar to reported effects of
phenobarbital in studies using systemic KA to induce SE in P10
[33,36] and older [48] rats. A surprising finding in the present
study was the limited efficacy of phenobarbital against seizure-
induced neuronal death in the model, despite the drug reducing
seizure severity. The explanation for such uncoupling between
seizures and damage with phenobarbital is uncertain. Phenobarbi-
tal may fail to prevent direct excitotoxicity in the model, or it is
possible that cortical seizures were suppressed, while intrahippo-
campal seizures continued. Concern remains that high doses of
anticonvulsants may promote neuronal apoptosis or suppress
neurogenesis in the developing brain although consistent with
other reports [34], we found phenobarbital was safe in P10 rats
when given alone at 25 mg/kg. Notably, even at the highest dose
tested (50 mg/kg), A-438079 alone did not promote cell death in
P10 rats. Together, these findings suggest a continuing need to
assess the safety of phenobarbital for the treatment of neonatal
seizures and SE in the immature brain [49,50].
Bumetanide has been reported to inhibit neonatal seizures in
P10 rats given systemic KA [36] as well as brief hypoxia-induced
seizures, neither of which are lesional insults. Here, we did not
observe seizure-suppressive effects of bumetanide in the P10
intra-amygdala KA model. A recent study also failed to detect an
effect of bumetanide at 0.15 mg/kg against hypoxia-induced sei-
zures when given alone [34]. This suggests bumetanide may not
be effective against all types of seizures in the immature brain. Of
course, we may have missed effects at other doses. The findings
suggest the P10 rat intra-amygdala KA model may not capture
effects of certain antiseizure compounds but nevertheless under-
scores the need for a range of models to be profiled [51]. Combin-
ing bumetanide with phenobarbital has been reported to produce
synergistic effects against neonatal seizures [34], but we did not
explore a combination of bumetanide with A-438079 in the pres-
ent study.
Our study identified some potential limitations of A-438079.
First, A-438079 passes into the brain following parenteral injec-
tion but is rapidly eliminated, possibly restricting the therapeutic
window of this compound. This may explain why A-438079 did
not completely suppress seizures at any dose. New P2X7R antago-
nists are in preclinical development with greater potency and
extended CNS stability [52] which may provide superior seizure-
suppressive effects and avoid some of the deleterious effects of
directly targeting GABA and glutamate receptors [53]. However,
translation of these results to clinical trials will likely require the
drug to be an “add-on”, for example to phenobarbital or where
frontline treatment has failed. In our studies, we did not observe
superior seizure suppression but addition of A-438079 may pro-
vide better neuroprotection than phenobarbital alone. We also
observed a U-shaped dose response with A-438079, with the high-
est dose having weaker effects on seizures and the protective
effects being lost. This suggests A-438079 may have off-target
effects, an idea which could be pursued in future using P2X7R
antagonists of a different chemical structure or with improved
specificity. Third, a number of additional studies will be needed.
This includes tests in another model(s), determining the role of
IL1b reduction in the seizure or neuroprotective effects, and deter-
mining whether preventing SE by targeting P2X7R has effects on
later-life cognitive impairments or epilepsy [30]. In summary, the
present study identifies seizure-suppressive and neuroprotective
effects of the P2X7R antagonist A-438079 against focal-onset SE
in immature rats. These findings may help inform future preclini-
cal test models and a novel focus for therapeutic approaches to
prolonged early-life seizures.
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